Why the study?
Thrombosis during pregnancy causes severe maternal and fetal complications, making effective thromboprophylaxis essential to optimize outcomes in high-risk pregnancies.
Effective thromboprophylaxis with LMWH and nonpharmacologic measures is essential in high-risk pregnancies, while emerging personalized and technological approaches hold promise for optimizing future care.
Answers are grounded in this paper and cite their sources.
LMWH remains standard thromboprophylaxis in high-risk pregnancies; emerging personalized and digital strategies require prospective validation before adoption.
Thrombosis during pregnancy poses a significant clinical challenge due to its potential for severe maternal and fetal complications. The incidence of thromboembolic events in pregnant women is heightened by pregnancy-associated hypercoagulability, venous stasis, and endothelial changes, all of which contribute to an elevated risk. Effective thromboprophylaxis is essential to mitigate these risks and improve outcomes for both mother and child. This review provides a comprehensive evaluation of current thromboprophylaxis strategies, including pharmacologic interventions such as low-molecular-weight heparins (LMWHs) and unfractionated heparin (UFH) and nonpharmacologic measures like compression stockings and lifestyle modifications. Additionally, the review explores emerging approaches, including personalized medicine strategies, novel anticoagulants, and technology-enabled monitoring solutions. By integrating current evidence with emerging trends, this review aims to offer insights into optimizing thromboprophylaxis in high-risk pregnancies, ultimately contributing to improved clinical outcomes and guiding future research directions in this critical area of maternal healthcare.
No takes yet. Share an insight, caveat, or question.
Dahiphale et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: